{"id":6645,"date":"2024-11-21T13:57:44","date_gmt":"2024-11-21T12:57:44","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6645"},"modified":"2025-04-28T21:34:56","modified_gmt":"2025-04-28T19:34:56","slug":"phase-1-2-study-of-the-pd-l1-inhibitor-bgb-a333-alone-and-in-combination-with-the-pd-1-inhibitor-tislelizumab-in-patients-with-advanced-solid-tumours","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/phase-1-2-study-of-the-pd-l1-inhibitor-bgb-a333-alone-and-in-combination-with-the-pd-1-inhibitor-tislelizumab-in-patients-with-advanced-solid-tumours\/","title":{"rendered":"Phase 1\/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6645","publication","type-publication","status-publish","hentry","disease_state-advanced-solid-tumors","disease_state-urothelial-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6645"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}